pharma news today glp-1 obesity health drugs october 2025 Outlook for obesity in 2025: more GLP-1 drugs transform obesity care,

Ready to embark on a safe, effective, and personalized weight loss journey

When a drug dissolves here, it can enter the bloodstream directly without passing through the gastrointestinal tract or undergoing first-pass metabolism in the liver

[1] [2] Semaglutide is not indicated for the treatment of type 1 diabetes

Any significant weight loss, regardless of method, results in some lean mass loss

In the same study, patients were followed for an additional 12 weeks after the last dose of bimagrumab and experienced no weight regain

These findings suggest that specific patterns of neural connectivity are linked to both metabolic control and cognitive performance in T2DM